Added to YB: 2026-04-03
Pitch date: 2026-04-01
CAMX.ST [bullish]
Camurus AB (publ)
-1.99%
current return
Author Info
No bio for this author
Company Info
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
Market Cap
SEK 27.9B
Pitch Price
SEK 493.40
Price Target
1.0K (+115%)
Dividend
N/A
EV/EBITDA
27.01
P/E
38.09
EV/Sales
10.72
Sector
Pharmaceuticals
Category
growth
Camurus (CAMX.ST) – Fighting the Opioid Crisis with a Platform Technology
CAMX.ST: Swedish pharma w/ FluidCrystal platform for long-acting injectables. Buvidal/Brixadi (OUD treatment) drives growth; 70K patients globally, targeting 100K by 2027. FY25 rev SEK 2.27B (+21% YoY), EPS SEK 12.26 (+70% YoY). Oclaiz FDA PDUFA June 10, '26 for acromegaly; GEP-NET data late '26. Zero debt, SEK 3.7B cash. Fair PE 26, PT SEK 1,040 (~30% annualized return to 2028). Risks: FDA approval, partner dependency, FX exposure.
Read full article (8 min)